Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026827 (hypotonia)
 5,860 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The results of cluster analysis of maternal mortality after cesarean section in the USSR are reported. The statistical data were collected for the 1980-1986 period for USSR in total and for various regions. Region A included Baltic republics and Byelorussia; region B included Russia, Ukraine, Armenia and Moldavia; region C included Uzbekistan, Kazakhstan, Kirgizia, Azerbaijan, and Georgia; and region D included Tadzhikistan and Turkmenia. In the USSR, cesarean section was performed in 1.6-3.1% of all pregnancies (2.4-4.6%, 1.8-3.7%, 0.9-1.9%, and 0.8- 1.5% in regions A, B, C and D, respectively). Mortality rate after cesarean section was 0.4-0.2% for the USSR (0.09-0.08%, 0.35-0.10%, 0.80-0.40%, and 1.60-0.50% for regions A, B, C and D, respectively). Indications for cesarean section included abruptio placentae (34.2%), late toxemia (22.9%), cicatrix in the uterus (8.7%), narrow pelvis (8.7%), anomaly of labor activity (8%), extragenital pathology (5.8%), placenta previa (5.1%), fetal distress (3.6%), and others (3%). Emergency cesarean section was performed in 90% of the patients (only 18% underwent emergency cesarean section within 1 hour after the diagnosis). The most frequent cause of death after cesarean section was hemorrhage (36.2%). The 2nd leading cause of death was late toxemia (17.5/%). Other causes of death included cerebral hemorrhage (8.1%), brain edema (9.8%), complications of anesthesia (9.5%), extragenital diseases (7.7%), and hypotonia of the uterus (5.6%).
 ...
PMID:[Mortality after cesarean section]. 273 99

Since 1992, Human Botulism Immune Globulin has been provided by the California Department of Health Services to infants with probable infant botulism, the intestinal toxemia form of human botulism. Human Botulism Immune Globulin became available in California in 1992-1997 within a randomized, controlled, double-blinded, pivotal clinical trial and subsequently became available nationwide in 1998-2003 in an open-label study until its licensure in October 2003 as BabyBIG. Thereafter, Human Botulism Immune Globulin remained available nationwide as an approved orphan-drug product. To achieve prompt neutralization of circulating botulinum toxin, the decision to treat with Human Botulism Immune Globulin has been based on clinical criteria that include a consistent history and physical findings of bulbar palsies, hypotonia, and weakness. After licensure, the charts of patients who did not have laboratory-confirmed infant botulism were reviewed to identify their actual diagnoses. The approximately 5% of 681 patients treated with Human Botulism Immune Globulin who did not have infant botulism fell into 5 categories: spinal muscular atrophy, metabolic disorders, other infectious diseases, miscellaneous, and probable infant botulism lacking laboratory confirmation.
 ...
PMID:Clinical mimics of infant botulism. 1740 57